(CIRB) Molecular Analysis for Therapy Choice (MATCH)

ECOG-EAY131
NCT02465060
Cancer - Anus, Cancer - Bones and Joints, Cancer - Brain and Nervous System, Cancer - Breast - Female, Cancer - Breast - Male, Cancer - Cervix, Cancer - Colon, Cancer - Corpus Uteri, Cancer - Esophagus, Cancer - Eye and Orbit, Cancer - Hodgkin's Lymphoma, Cancer - Ill-Defined Sites, Cancer - Kidney, Cancer - Larynx, Cancer - Lip, Oral Cavity and Pharynx, Cancer - Liver, Cancer - Lung, Cancer - Melanoma, skin, Cancer - Multiple Myeloma, Cancer - Non-Hodgkin's Lymphoma, Cancer - Other Digestive Organ, Cancer - Other Female Genital, Cancer - Other Male Genital, Cancer - Other Respiratory and Intrathoracic Organs, Cancer - Other Skin, Cancer - Other Urinary, Cancer - Ovary, Cancer - Pancreas, Cancer - Prostate, Cancer - Rectum, Cancer - Small Intestine, Cancer - Soft Tissue, Cancer - Stomach, Cancer - Thyroid, Cancer - Unknown Sites, Cancer - Urinary Bladder
Tara Seery
Open
Treatment
AZD4547, AZD5363, AZD9291, BIBW 2992 (Afatinib), Binimetinib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, GDC-0449, GSK2636771, Nivolumab, Palbociclib, Sprycel, Sunitinib, Sutent, TRAMETINIB, Taselisib (GDC-0032), Trastuzumab Emtansin
II
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.